Jefferies notes Healius' positive outlook for its pathology business

Healius

17/11/2024 23:06

** Jefferies says Healius  HLS.AX  sees strong second half
growth for its pathology business    
    ** Analysts at Jefferies forecast for HLS' pathology
business an EBIT margin of 1.1% in 1HFY25 and 4.6% 2HFY25
    ** The Aussie healthcare firm said on Friday it sees 1H25
EBIT for its pathology business broadly in line with 1H24, while
anticipating an increase in pathology earnings in 2HFY25
    ** Company's 1HFY24 EBIT was A$6 million ($3.88 million)
while Jefferies estimate was A$7 million
    ** Brokerage says HLS's elevated cost base continues to be
an issue
    ** Brokerage cuts price target for co to A$1.45 from A$1.75;
retains "hold" rating
    ** HLS down 18.4% so far this year as of last close,
underperforming against a 3.7% gain on the ASX Health Care index
 .AXHJ 


($1 = 1.5482 Australian dollars)

 (Reporting by Nikita Maria Jino in Bengaluru)
 ((Nikita.Jino@thomsonreuters.com;))